[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629756":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":18,"locations":24,"responsibleParty":40,"collaborators":10,"id":44,"slug":10,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":10,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":10,"maxAge":10,"enrollmentInfo":51,"targetDuration":10,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":10,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Extension Cohort",null,"Patients with squamous NSCLC who participated in the RATIONALE-307 trial and had no documented death before study completion",[13],"Other: No intervention",[15],{"type":6,"name":16,"description":16,"armGroupLabels":17,"otherNames":10},"No intervention",[9],[19],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Zhijie Wang, MD","CONTACT","+86 13466323860","jie_969@163.com",[25],{"facility":26,"status":27,"city":28,"state":10,"zip":10,"country":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"National Cancer Center\u002FNational Clinical Research Center for Cancer\u002FCancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","RECRUITING","Beijing","China",{"type":31,"coordinates":32},"Point",[33,34],116.39723,39.9075,{"lat":34,"lon":33},[37],{"name":38,"role":21,"phone":39,"phoneExt":10,"email":23},"Wang Zhijie","+8613466323860",{"type":41,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Zhijie Wang","Chief Physician","100629756",false,"NCT07478809","A Retrospective Real-World Study Based on RATIONALE-307","Long-Term Efficacy and Safety Analysis of First-Line Tislelizumab in Patients With Advanced Squamous NSCLC: a Retrospective Real-World Study Based on RATIONALE-307","Inclusion Criteria:\n\n* Patients with squamous NSCLC who participated in the RATIONALE-307 trial and had no documented death before study completion\n\nExclusion Criteria:\n\n* Patients who had a documented death before study completion in the RATIONALE-307 trial","ALL",{"count":52,"type":53},109,"ESTIMATED","OBSERVATIONAL","The study aims to retrospectively collect long-term survival data from patients who received first-line tislelizumab combined with chemotherapy in the RATIONALE-307 trial, in order to enrich the evidence on long-term benefits in advanced squamous NSCLC patients from immunotherapy and to identify patients deriving greater clinical advantage.",[57],"NSCLC (Advanced Non-small Cell Lung Cancer)","2026-03-23",{"date":60,"type":61},"2026-03-27","ACTUAL",{"date":63,"type":61},"2026-02-28",{"date":65,"type":53},"2027-12-31",{"name":5,"class":6},1]